Abciximab

Phase 3Terminated

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Stroke

Conditions

Stroke

Trial Timeline

Mar 1, 2005 → May 1, 2005

NCT ID

NCT00167765

About Abciximab

Abciximab is a phase 3 stage product being developed by Eli Lilly for Stroke. The current trial status is terminated. This product is registered under clinical trial identifier NCT00167765. Target conditions include Stroke.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00178451	Phase 1/2	Withdrawn	—	—	Carotid Stenosis
NCT00440895	Approved	Completed	Feb 1, 2007	May 1, 2013	Myocardial Infarction
NCT00440778	Approved	Completed	Feb 1, 2007	Oct 1, 2008	Myocardial Infarction
NCT00420030	Approved	Completed	Sep 1, 2006	Jun 1, 2009	Shock, Cardiogenic
NCT00354406	Approved	Completed	Apr 1, 2006	Dec 1, 2008	Myocardial Infarction
NCT00167765	Phase 3	Terminated	Mar 1, 2005	May 1, 2005	Stroke
NCT00126139	Phase 3	Terminated	Apr 1, 2004	May 1, 2005	Stroke
NCT00073372	Phase 3	Terminated	Oct 1, 2003	Dec 1, 2005	Cerebrovascular Accident
NCT00169819	Approved	Completed	Oct 1, 2003	Apr 1, 2006	Coronary Artery Disease

Competing Products

20 competing products in Stroke

See all competitors

Product	Company	Stage	Hype Score
SPT-07A injection	Sinopharm	Phase 3	76
Osmotic drugs	Sinopharm	Pre-clinical	22
Aspirin, Clopidogrel	Yuhan	Pre-clinical	23
DS-1040b + Placebo	Daiichi Sankyo	Phase 1/2	41
SUN13837 + placebo	Daiichi Sankyo	Phase 2	52
DS-1040b + Aspirin	Daiichi Sankyo	Phase 1	33
piclozotan low dose + placebo + piclozotan high dose	Daiichi Sankyo	Phase 2	52
DS1040b + Placebo	Daiichi Sankyo	Pre-clinical	23
Pharmacological intensification based on olmesartan	Daiichi Sankyo	Phase 2	52
warfarin tablets + Edoxaban tablets (high dose regimen-60mg) + Edoxaban tablets (low dose regimen-30mg) + placebo warfarin + placebo edoxaban	Daiichi Sankyo	Phase 3	77
YM872 (zonampanel), t-PA (alteplase)	Astellas Pharma	Phase 2	52
ASP2246	Astellas Pharma	Phase 1/2	41
Neu2000KWL + Neu2000KWL + Neu2000KWL + Placebos	Sun Pharmaceutical	Phase 2	52
XY03-EA + XY03-EA Placebo	Sun Pharmaceutical	Phase 2	52
Redasemtide + Placebo	Shionogi	Phase 2	52
Statin	Shionogi	Approved	85
Alteplase	Kyowa Kirin	Approved	85
ONO-2506 + ONO-2506 + ONO-2506	Ono Pharmaceutical	Phase 2/3	65
Abciximab	Eli Lilly	Phase 3	77
SB623 Implant (2.5M) + SB623 Implant (5.0M)	Sumitomo Pharma	Phase 2	52

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved